Your browser doesn't support javascript.
loading
BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.
Fang, Jiamin; Zhou, Fuling.
Afiliação
  • Fang J; Department of Hematology, Zhongnan Hospital of Wuhan University, No.169 Donghu Road, Wuhan, 430072, China.
  • Zhou F; Department of Hematology, Zhongnan Hospital of Wuhan University, No.169 Donghu Road, Wuhan, 430072, China. zhoufuling@whu.edu.cn.
Ann Hematol ; 103(4): 1069-1083, 2024 Apr.
Article em En | MEDLINE | ID: mdl-37704875
Recently, many new therapies have improved the outcomes of patients with relapsed and/or refractory multiple myeloma (RRMM). Nevertheless, recurrence is still unavoidable, and better treatment choices for RRMM are urgently needed. The clinical success of Chimera antigen receptor (CAR) T cell therapy in many hematological diseases, including leukemia and lymphoma, has drawn considerable attention to RRMM. As CAR T cell therapy continues to mature and challenge traditional therapies, it is gradually changing the treatment paradigm for MM patients. The B cell maturation antigen (BCMA), expressed in malignant plasma cells but not normal ones, is an ideal target for MM treatment, due to its high expression. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) has approved two BCMA-targeting CAR T cell products, idecabtagene vicleucel (Ide-cel) and ciltacabtagene autoleucel (Cilta-cel), for use in RRMM. In this review, we focus on data from RRMM patients involved in clinical trials of Ide-cel and Cilta-cel and discuss the present situation and future direction of CAR T cell therapy for this condition.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Plasmócitos / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Plasmócitos / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article